Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Affiliations

• ¹ Plymouth University Medical School, Plymouth, UK. Simon.Rule@nhs.net.
• ² Department of Hematology, Jagiellonian University, Krakow, Poland.
• ³ Skånes University Hospital, Lund University, Lund, Sweden.
• ⁴ Hematology Division, Hematology and Oncology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
• ⁵ Ist Dept Medicine, Charles University General Hospital, Prague, Czech Republic.
• ⁶ Departement Oncologie, UZ Gent, Ghent, Belgium.
• ⁷ Instituto Biosanitario de Salamanca, Hospital Clinico Universitario Salamanca, Salamanca, Spain.
• ⁸ Institutto Português de Oncologia de Lisboa, Portugal and Champalimaud Centre for the Unknown, Hematology, Lisbon, Portugal.
• ⁹ Klinikum der Ruprechts-Karls-Universität Heidelberg, Med. Klinik u. Poliklinik V, Heidelberg, Germany.
• ¹⁰ Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University, Mainz, Germany.
• ¹¹ The Ottawa Hospital, General Campus, Ottawa, ON, Canada.
• ¹² Seoul St. Mary's Hospital, Seocho-gu, Seoul, South Korea.
• ¹³ APHP, Saint-Louis Hospital, Hemato-oncology, Diderot University, Paris, France.
• ¹⁴ Janssen Research & Development, Raritan, NJ, USA.
• ¹⁵ Janssen Research & Development, Leiden, The Netherlands.
• ¹⁶ Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany.